Genetic modifiers of the p53 pathway

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 4, 2016, Pages

  Basu, Subhasree ^a   Murphy, Maureen E ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

3' UNTRANSLATED REGION; ARTICLE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; GENETICS; HUMAN; NONHUMAN; PROMOTER REGION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENE DELETION; MODIFIER GENE; MUTATION; NEOPLASM; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

GENE DELETION; GENE FREQUENCY; GENES, MODIFIER; GENES, P53; HUMANS; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS;

EID: 84962362271     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a026302     Document Type: Article

References (85)

1. Aguilo F, Zhou MM, Walsh MJ. 2011. Long noncodingRNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res 71: 5365-5369.
2. Atwal GS, Kirchhoff T, Bond EE, Montagna M, Menin C, Bertorelle R, Scaini MC, Bartel F, Bohnke A, Pempe C, et al. 2009. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci 106: 10236-10241.
3. Azzam GA, Frank AK, Hollstein M, Murphy ME. 2011. Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle 10: 1352-1355.
4. Bandele OJ, Wang X, Campbell MR, Pittman GS, Bell DA. 2011. Human single-nucleotide polymorphisms alter p53 sequence-specific binding at gene regulatory elements. Nucleic Acids Res 39: 178-189.
5. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L. 1994. Is p53 polymorphism aintained by natural selection? Hum Hered 44: 266-270.
6. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, et al. 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3: 387-402.
7. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S. 2006. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98: 911-919.
8. Bojesen SE, Nordestgaard BG. 2008. The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle 7: 158-163.
9. Bonafe M, Salvioli S, Barbi C, Mishto M, Trapassi C, Gemelli C, Storci G, Olivieri F, Monti D, Franceschi C. 2002. p53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes. Biochem Biophys Res Commun 299: 539-541.
10. Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, et al. 2003. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 9: 4860-4864.
11. Bonafe M, Salvioli S, Barbi C, Trapassi C, Tocco F, Storci G, Invidia L, Vannini I, Rossi M, Marzi E, et al. 2004. The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. Cell Death Differ 11: 962-973.
12. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al. 2004. A single nucleotide polymorphism in theMDM2promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
13. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, et al. 2006. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104-5110.
14. Bonfigli AR, Sirolla C, Testa R, Cucchi M, Spazzafumo L, Salvioli S, Ceriello A, Olivieri F, Festa R, Procopio AD, et al. 2013. The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: A cross-sectional study. Acta Diabetol 50: 429-436.
15. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, et al. 2006. Impact of the MDM2SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43: 531-533.
16. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, Fornace AJ. 1999. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 18: 6845-6854.
17. Burgdorf KS, Grarup N, Justesen JM, Harder MN, Witte DR, Jorgensen T, Sandbaek A, Lauritzen T, Madsbad S, Hansen T, et al. 2011. Studies of the association of Arg72-Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans. PLoS ONE 6: e15813.
18. Congrains A, Kamide K, Ohishi M, Rakugi H. 2013. ANRIL: Molecular mechanisms and implications in human health. Int J Mol Sci 14: 1278-1292.
19. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. 2003. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365.
20. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, et al. 2013. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 45: 385-391, 391. e381-382.
21. Denisov EV, Cherdyntseva NV, Litviakov NV, Malinovskaya EA, Babyshkina NN, Belyavskaya VA, Voevoda MI. 2012. TP53 gene polymorphisms in cancer risk: The modulating effect of ageing, ethnicity and TP53 somatic abnormalities. In Tumor suppressor genes (ed. Cheng DY). InTech, Rijeka, Croatia.
22. Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC. 1993. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 53: 752-759.
23. Feng Z, Zhang C, Kang HJ, Sun Y, Wang H, Naqvi A, Frank AK, Rosenwaks Z, Murphy ME, Levine AJ, et al. 2011. Regulation of female reproduction by p53 and its family members. FASEB J 25: 2245-2255.
24. Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, Hollstein M, Murphy ME. 2011. The codon 72 polymorphism of p53 regulates interaction with NF-kB and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 31: 1201-1213.
25. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al. 2012.Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148: 244-258.
26. Gansmo LB, Knappskog S, Romundstad P, Hveem K, Vatten L, Lonning PE. 2015. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. Int J Cancer 137: 96-103.
27. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS, et al. 2013. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 45: 392-398, 398e1-2.
28. Gaspari L, Pedotti P, Bonafe M, Franceschi C, Marinelli D, Mari D, Garte S, Taioli E. 2003.Metabolic gene polymorphisms and p53 mutations in healthy centenarians and younger controls. Biomarkers 8: 522-528.
29. Gaulton KJ, Willer CJ, Li Y, Scott LJ, Conneely KN, Jackson AU, Duren WL, Chines PS, Narisu N, Bonnycastle LL, et al. 2008. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes 57: 3136-3144.
30. Grochola LF, Zeron-Medina J, Meriaux S, Bond GL. 2010. Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol 2: a001032.
31. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V. 1986. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6: 4650-4656.
32. Harris SL, Gil G, Robins H, Hu W, Hirshfield K, Bond E, Bond G, Levine AJ. 2005. Detection of functional singlenucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci 102: 16297-16302.
33. Hirshfield KM, Rebbeck TR, Levine AJ. 2010. Germline mutations and polymorphisms in the origins of cancers in women. J Oncol 2010: 297671.
34. Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JIJ, Khaku S, Cai KQ, Campbell MR, Porter DK, Wang X, et al. 2015. An African-specific polymorphic variant in the TP53 gene impairs tumor suppressor function. Drexel University, Philadelphia, PA.
35. Jeong BS, Hu W, Belyi V, Rabadan R, Levine AJ. 2010. Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J 24: 1347-1353.
36. Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R, Ciosek SL, Doody DR, Smith LM, Weaver J, et al. 2009. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 41: 811-815.
37. Kang HJ, Feng Z, Sun Y, Atwal G, Murphy ME, Rebbeck TR, Rosenwaks Z, Levine AJ, Hu W. 2009. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci 106: 9761-9766.
38. Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD. 2013. Fibrinogen and future cardiovascular disease in peoplewith diabetes: Aetiological associations and risk prediction using individual participant data from nine community-based prospective cohort studies. Diab Vasc Dis Res 10: 143-151.
39. Knappskog S, Lonning PE. 2011. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget 2: 251-258.
40. Knappskog S, Bjornslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, et al. 2011. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell 19: 273-282.
41. Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, Romundstad P, Hveem K, Vatten L, Salvesen HB, Lonning PE. 2012. SNP285C modulates oestrogen receptor/Sp1 binding to theMDM2promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer 48: 1988-1996.
42. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, Xiong Y. 2011. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 30: 1956-1962.
43. Kung CP, Khaku S, Jennis M, Zhou Y, Murphy ME. 2015. Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes. Mol Cancer Res 13: 250-262.
44. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, et al. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
45. Li X, Dumont P, Della Pietra A, Shetler C, Murphy ME. 2005. The codon 47 polymorphism in p53 is functionally significant. J Biol Chem 280: 24245-24251.
46. Liu J, Tang X, Li M, Lu C, Shi J, Zhou L, Yuan Q, Yang M. 2013. Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility. Breast Cancer Res Treat 140: 151-157.
47. Ma YY, Guan TP, Yao HB, Yu S, Chen LG, Xia YJ, He XJ, Wang HJ, Jiang XT, Tao HQ. 2013. The MDM2 309T.G polymorphism and ovarian cancer risk: A meta-analysis of 1534 cases and 2211 controls. PLoS ONE 8: e55019.
48. Marin MC, Jost CA, Brooks LA, Irwin MS, O’Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, et al. 2000. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25: 47-54.
49. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. 1987. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7: 961-963.
50. McGregor JM, Harwood CA, Brooks L, Fisher SA, Kelly DA, O’Nions J, Young AR, Surentheran T, Breuer J, Millard TP, et al. 2002. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 119: 84-90.
51. Menendez D, Krysiak O, Inga A, Krysiak B, Resnick MA, Schonfelder G. 2006. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci 103: 1406-1411.
52. Montes R, Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
53. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, et al. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862.
54. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
55. Parry DJ, Grant PJ, Scott DJA. 2004. Atherothrombotic risk factor clustering in healthy male relatives of male patients with intermittent claudication. J Vasc Surg 40: 891-898.
56. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
57. Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. 2010. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: A report from the Children’s Oncology Group. Pediatr Blood Cancer 55: 248-253.
58. Pietsch EC, Humbey O, Murphy ME. 2006. Polymorphisms in the p53 pathway. Oncogene 25: 1602-1611.
59. Pim D, Banks L. 2004. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199.
60. Post SM, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, et al. 2010. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 18: 220-230.
61. Qin X, Peng Q, Tang W, Lao X, Chen Z, Lai H, Deng Y, Mo C, Sui J, Wu J, et al. 2013. An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk. PLoS ONE 8: e76031.
62. Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R, Huddart RA, Renwick A, Hughes D, Hines S, Seal S, et al. 2009. A genome-wide association study of testicular germ cell tumor. Nat Genet 41: 807-810.
63. Roth J, Koch P, Contente A, Dobbelstein M. 2000. Tumorderived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain. Oncogene 19: 1834-1842.
64. Sakamuro D, Sabbatini P, White E, Prendergast GC. 1997. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15: 887-898.
65. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, et al. 2007. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67: 9584-9590.
66. Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O, Meyer F, Roessner A. 2004. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 6: 529-535.
67. Shi H, Tan SJ, Zhong H, Hu W, Levine A, Xiao CJ, Peng Y, Qi XB, Shou WH, Ma RL, et al. 2009. Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet 84: 534-541.
68. Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC, Sabapathy K. 2005. Evidence for selective expression of the p53 codon 72 polymorphs: Implications in cancer development. Cancer Epidemiol Biomarkers Prev 14: 2245-2252.
69. Stegeman S, Moya L, Selth LA, Spurdle AB, Clements JA, Batra J. 2015. A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer. Endocr Relat Cancer 22: 265-276.
70. Sucheston L, Witonsky DB, Hastings D, Yildiz O, Clark VJ, Di Rienzo A, Onel K. 2011. Natural selection and functional genetic variation in the p53 pathway. Hum Mol Genet 20: 1502-1508.
71. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, et al. 2004. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23: 3328-3337.
72. Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, Freedman ML, Kantoff PW. 2010. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res 16: 5244-5251.
73. Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD, Moriuchi T. 2001. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 22: 515-517.
74. Toledo F, Lee CJ, Krummel KA, Rodewald LW, Liu CW, Wahl GM. 2007. Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol Cell Biol 27: 1425-1432.
75. Tomso DJ, Inga A, Menendez D, Pittman GS, Campbell MR, Storici F, Bell DA, Resnick MA. 2005. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. ProcNatl Acad Sci 102: 6431-6436.
76. Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, Ricketts M, Linger R, Nsengimana J, Deloukas P, et al. 2010. Variants near DMRT1, TERTand ATF7IP are associated with testicular germ cell cancer. Nat Genet 42: 604-607.
77. Vousden KH, Prives C. 2009. Blinded by the light: The growing complexity of p53. Cell 137: 413-431.
78. Walker KK, Levine AJ. 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci 93: 15335-15340.
79. Wang X, Pittman GS, Bandele OJ, Bischof JJ, Liu G, Brothers JF II, Spira A, Bell DA. 2014. Linking polymorphic p53 response elements with gene expression in airway epithelial cells of smokers and cancer risk. Hum Genet 133: 1467-1476.
80. Weige CC, Birtwistle MR, Mallick H, Yi N, Berrong Z, Cloessner E, Duff K, Tidwell J, Clendenning M, Wilkerson B, et al. 2014. Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans. Mol Cancer Res 12: 1029-1041.
81. Whibley C, Pharoah PD, Hollstein M. 2009. p53 polymorphisms: Cancer implications. Nat Rev Cancer 9: 95-107.
82. Wynendaele J, Bohnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, Sbrzesny N, Kubitza D, Wolf A, Gradhand E, et al. 2010. An illegitimate microRNA target site within the 30 UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res 70: 9641-9649.
83. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, Gil J, Walsh MJ, Zhou MM. 2010. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38: 662-674.
84. Zeron-Medina J, Wang X, Repapi E, Campbell MR, Su D, Castro-Giner F, Davies B, Peterse EF, Sacilotto N, Walker GJ, et al. 2013. A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection. Cell 155: 410-422.
85. Zhuo W, Zhang L, Zhu B, Ling J, Chen Z. 2012. Association of MDM2 SNP309 variation with lung cancer risk: Evidence from 7196 cases and 8456 controls. PLoS ONE 7: e41546.